|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of diabetes increased FGF21 levels and both of the treatments could reduce its contents, however, glibenclamide was more effective than HESS.
|
31655149 |
2020 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, we aim to examine whether FGF-21 regulates expression of intestinal SGLT1 in diabetes.
|
30551357 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF21) is closely linked with metabolic disorders including diabetes.
|
31205953 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher levels of FGF21 were expressed, particularly in patients with diabetes.
|
30959789 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease.
|
31798902 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.
|
31721467 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF-21) is an important regulator in glycolipid metabolism that is a promising drug candidate for treatment of diabetes and obesity.
|
31129207 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes studies of the possible involvement of dietary methionine restriction in improving insulin resistance, glucose homeostasis, oxidative stress, lipid metabolism, the pentose phosphate pathway (PPP), and inflammation, with an emphasis on the fibroblast growth factor 21 and protein phosphatase 2A signals and autophagy in diabetes.
|
29603632 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating FGF21 level was independently associated with CIN (aOR: 4.66, 95% CI: 1.29-16.86, p = 0.019) and renal function decline (aHR: 7.98, 95% CI: 4.07-15.66, p < 0.001) whether diabetes was present or not.
|
30127382 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the past decade, there has been an enormous effort made to understand the physiological roles of FGF21 in regulating metabolism and to identify the mechanism for its potent pharmacological effects to reverse diabetes and obesity.
|
29727594 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection.
|
29634312 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous studies have been conducted to establish and confirm whether FGF21 exerts beneficial effects on obesity and diabetes along with its complications.
|
29989062 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed whether plasma concentrations of three known myokines [myonectin, myostatin, and fibroblast-derived growth factor 21 (FGF-21)] would be associated with direct and indirect indicators of insulin resistance (IR) in individuals who did not have a diagnosis of diabetes.
|
29445355 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21-responsiveness machinery in adipose tissue.
|
30043445 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, hepatic TTP posttranscriptionally regulates systemic insulin sensitivity in diabetes through liver-derived FGF21.
|
29997282 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, FGF-21 was found to have anti-inflammatory effect, to our knowledge, the effect of FGF-21 on inflammatory state in diabetes has not been elucidated.
|
29414665 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metallothionein can modulate various stress-induced signaling pathways (mitogen-activated protein kinase, Wnt, nuclear factor-κB, phosphatidylinositol 3-kinase, sirtuin 1/AMP-activated protein kinase and fibroblast growth factor 21) to alleviate diabetes and diabetic complications.
|
29072367 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF21), liver-derived hormone, exerts diverse metabolic effects, being considered for clinical application to treat obesity and diabetes.
|
28374855 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of serum FGF21 with subclinical stages of diabetic nephropathy may unearth perspectives on early detection and prevention of the advanced stages of chronic diabetes microvascular complications through effective FGF21-targeted therapy.
|
28181108 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration.
|
28580278 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported that FGF21 is expected to become a new drug for treatment of diabetes.
|
28143735 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we prospectively evaluated the sex-specific association between FGF-21 and diabetes in a Chinese population.
|
29021814 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG.
|
27611701 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGF21 prevents the onset of diet-induced diabetes, without changing body fat mass.
|
28770320 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations of fibroblast growth factor 21 with cardiovascular risk and β-cell function in patients who had no history of diabetes.
|
28735064 |
2017 |